Review article: The treatment of refractory Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 11, 2003, Pages 1333-1343

  Megraud F ^a   Lamouliatte, H ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL VACCINE; BISMUTH CITRATE; BISMUTH DERIVATIVE; BISMUTH SALICYLATE; CEFALEXIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; FURAZOLIDONE; MACROLIDE; METRONIDAZOLE; NITROFURANTOIN; OMEPRAZOLE; PENICILLIN G; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE BISMUTH CITRATE; RIFABUTIN; RIFAMYCIN; STOMACH SECRETION INHIBITOR; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG CHOICE; EMPIRICISM; ERADICATION THERAPY; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION PREVENTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; STOMACH MUCOSA; STOMACH PH; STOMACH SECRETION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0038095640     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01592.x     Document Type: Review

References (90)

1. Mégraud F, Lamouliatte H. Helicobacter pylori and duodenal ulcer. Evidence suggesting causation. Dig Dis Sci 1992; 37: 769-72.
2. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997; 41: 8-13.
3. The report of the Digestive Health Initiative International Update on Helicobacter pylori. Gastroenterology 1997; 113: S4-5.
4. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pulori infection. J Gastroenterol Hepatol 1998; 13: 1-12.
5. Hunt RH, Fallone CA, Thomson ABR. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Can J Gastroenterol 1999; 13: 213-7.
6. Coelho LG, Leon-Barua R, Quigley EMM. and representatives of the Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Latin-American consensus conference on Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 2688-91.
7. Malfertheiner P, Mégraud F, O'Morain C, et al. and the European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
8. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helieobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000; 32: 1659-64.
9. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 28: 939-42.
10. Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995; 41: 1-4.
11. Wotherspoon AC, Doglioni C, de Boni M, Spencer J, Isaacson PG. Antibiotic treatment for low-grade gastric MALT lymphoma, Lancet 1994; 11(343): 1503.
12. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 24: 345: 1591-4.
13. Ruskoné-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment, Gut 2001; 48: 297-303.
14. Liu H, RuskonéFourmestraux A, Lavergne-Slove A, et al. Resistance of t(11:18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357: 39-40.
15. Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F. Risk factors for failure of Helicobacter pylori therapy. Results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99-109.
16. Wermeille J, Cunningham M, Dederding JP, et al. Echec de l'éradication d'Helicobacter pylori: l'observance est-elle la principale cause? Gastroenterol Clin Biol 2002; 26: 216-9.
17. Mégraud F, Hazell S, Glupczynski Y. Antibiotic susceptibility and resistance. In: Mobley HLT, Mendz GL, Hazell SL, eds. Helicobacter pylori: Physiology and Genetics. Washington DC: ASM Press. 2001: 511-30.
18. Lederberg J, Lederberg EM. Replica plating and indirect selection of bacterial mutants. J Bacteriol 1952; 63: 399-406.
19. Occhialini A, Urdaci M, Doucet-Populaire F, Bébéar CM, Lamoullatte H, Mégraud F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997; 41: 2724-8.
20. Goodwin CS, McNulty CAM. Bacteriological and pharmacological basis for the treatment of Helicobacter pylori infection. In: Rathbone BJ, Heatly RV, eds. Helicobacter pylori and Gastroduodenal Disease. 2nd edn. Oxford: Blackwell Scientific Publications, 1992: 224-31.
21. Mégraud F. Helicobacter pylori and macrolides. In: Schönfeld W. Kirst HA, eds. Macrolide antibiotics. Berlin: Birkhauser. 2002: 243-60.
22. Mégraud F. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in vitro. J Clin Gastroenterol 1995; 20(Suppl. 1): S24-7.
23. Hirschowitz BI, Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther 2001; 15: 87-103.
24. Labenz J, Stolte M, Blum AL, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39-43.
25. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther 2001; 70: 484-92.
26. Kita T, Sakaeda T, Aoyama N, et al. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. Biol Pharm Bull 2002; 25: 923-7.
27. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxicillin and clarithromycin in Japan. Dig Liver Dis 2001; 33: 671-65.
28. Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2 C 19 genetic polymorphlsm. Aliment Pharmacol Ther 2001; 15: 1479-84.
29. Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003; 15: 27-33.
30. Debongnie JC, Pauwels S, Raat A, de Meeus Y, Haot J, Mainguet P. Quantification of Helicobacter pylori infection in gastritis and ulcer disease using a simple and rapid carbon 14-urea breath test. J Nucl Med 1991; 32: 1192-8.
31. Moshkowitz M, Konikoff FM, Peled Y, et al. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995; 36: 845-7.
32. Sheu BS, Yang HB, Su IJ, Shiesh SC, Chi CH, Lin XZ. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc 1996; 44: 683-8.
33. Perri F, Clemente R, Festa V, et al. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol 1998; 30: 146-50.
34. Masconi G, Parente F, Russo A, Vago L, Imbesi V, Porro GB. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001; 96: 359-66.
35. Armstrong JA, Wee SH, Goodwin CS, Wilson DH. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro - an ultrastructural study. J Med Microbiol 1987; 24: 343-50.
36. Baena JM, Lopez C, Hidalgo A, et al. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol 2002; 14: 291-6.
37. Wyle FA, Tarnawski A, Schulman D, Dabros W. Evidence for gastric mucosal cell invasion by C. pylori: an ultrastructural study. J Clin Gastroenterol 1990; 12(Suppl. 1): S92-8.
38. Ko GH, Kang SM, Kim YK, et al. Invasiveness of Helicobacter pylori into human gastric mucosa. Helicobacter 1999; 4: 77-81.
39. Engstrand L, Graham D, Scheynius A, Genta RM, El-Zaatari F. Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol 1997; 108: 504-9.
40. Andersen LP, Blom J, Nielsen H, Survival and ultrastructural changes of Helicobacter pylori after phagocytosis by human polymorphonuclear leukocytes and monocytes. APMIS 1993; 101: 61-72.
41. Allen LA. Intracellular niches for extracellular bacteria: lessons from Helicobacter pylori. J Leukoc Biol 1999; 66: 753-6.
42. Evans DG, Evans DJ Jr, Graham DY. Adherence and internalization of Helicobacter pylori by Hep-2 cells. Gastroenterology 1992; 102: 1557-67.
43. Wilkinson SM, Uhl JR, Kline BC, Cockerill FR 3rd. Assessment of invasion frequencies of cultured Hep-2 cells by clinical isolates of Helicobacter pylori using an acridine orange assay. J Clin Pathol 1998; 51: 127-33.
44. Bjorkholm B, Zhukhovitsky V, Lofman C, et al. Helicobacter pylori entry into human gastric epithelial cells; a potential determinant of virulence, persistence, and treatment failures. Helicobacter 2000; 5: 148-54.
45. Amieva MR, Salama NR, Tompkins LS, Falkow S. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol 2002; 4: 677-90.
46. Matysiak-Budnik T, Heyman M, Candalh C, Lethuaire D, Mégraud F. In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier. J Antimicrob Chemother 2002; 50: 865-72.
47. Atherton JC, Cockayne A, Balsitis M, et al. Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxicillin and cimetidine. Gut 1995; 42: 1821-34.
48. Veldhuyzen van Zanten SJO, Dixon MF, Lee A. The gastric transitional zones: neglected links between gastroduodenal pathology and Helicobacter ecology. Gastroenterology 1999; 116: 1217-29.
49. Cellini L, Allocati N, Angelucci D, et al. Coccoid Helicobacter pylori not culturable in vitro reverts in mice. Microbiol Immunol 1994; 38: 843-50.
50. Kusters JG, Gerrits MM, Van Strijp JA, Vandenbroucke-Grauls CM. Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death. Infect Immun 1997; 65: 3672-9.
51. Lee A. Elimination of Helicobacter pylori is dependent on a Th2 response. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure 2000. London: Kluwer Academic Publisher, 2000: 187-91.
52. Borody T, Ren Z, Pang G, Clancy R. Impaired host immunity contributes to Helicobacter pylori eradication failure. Am J Gastroenterol 2002; 97: 3032-7.
53. Mohammadi M, Nedrud J, RedIine R. Murine CD4T-cell response to Helicobacter infection: Th1 cells enhance gastritis and Th2 cells reduce bacterial load. Gastroenterology 1997; 113: 1848-57.
54. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 45-51.
55. Lamouliatte H, The Aquitaine Gastro Association, Samoyeau R, de Mascarel A, Mégraud F. Double vs. single dose of pantoprazole, in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999; 13: 1523-30.
56. Perri F, Festa V, Merla A, Ouitadamo M, Clemente R, Andriulli A. Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. Helicobacter 2002; 7: 99-104.
57. Mégraud F, Lehn N, Lind R, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial. The MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-52.
58. Houben MHMG, VandeBeek D, Hensen EF, et al. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-55.
59. Graham DY, Osato MS, Hoffman J, et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther 2000; 14: 745-50.
60. Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111: 358-67.
61. Shore PA, Brodie BB, Hogben CAM. The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 1957; 119: 361-9.
62. Perri F, Festa V, Clemente R, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58-62.
63. Otero W, Gutierrez O, Eradication de H. pylori con terapia triple: bismuto, furazolidona, tetraciclina. Acta Med Col 1996; 21: 218.
64. Lamarque D, Tankovic J, Berrhouma A, et al. Triple therapy using ciprofioxacin for eradication of clarithromycin and metronidazole-resistant Helicobacter pylori. Gut 1997; 41(Suppl, 1): A104(Abstract).
65. Di Caro S, Ojetti V, Zocco MA, et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 517-32.
66. Cabrita J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area. Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-31.
67. Whitehead MW, Phillips RH, Sieniawska CE, et al. Double-blind comparison of absorbable colloidal bismuth subcitrate and nonabsorbable bismuth subnitrate in the eradication of Helicobacter pylori and the relief of nonulcer dyspepsia. Helicobacter 2000; 5: 169-75.
68. Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: 207-10.
69. Sakamato I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001; 47: 709-10.
70. Felley C, Corthesy-Theulaz I, Blanco Rivero JL, et al. Favourable effect of an acidified milk (LC1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001; 23: 25-9.
71. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000; 14: 1625-9.
72. Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999; 60: 203-9.
73. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744-9.
74. Armuzzi A, Cremonini F, Ojetti V, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study, Digestion 2001; 63: 1-7.
75. Al-Aiden FA, McElnay JC, Scott MG, McConnell JB, Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br J Pharmacol 2002; 53: 163-71.
76. Hojo M, Miwa H, Nagahara N, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 17: 691-700.
77. O'Morain C, Borody T, Farley A, et al. Efficacy and safety of single triple capsule of bismuth biskalcitrate, metronidazole and tetracycline given with omeprazole for eradication of Helicobacter pylori: international multicentre study. Aliment Pharmacol Ther 2003; 17: 415-20.
78. Fakheri H, Malekzadeh R, Merat S, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001; 15: 411-6.
79. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002; 7: 225-31.
80. Lamouliatte H, Mégraud F, Delchier JC, et al. Second-line treatment in case of failure to eradicate Helicobacter pylori: evaluation of four treatment strategies, Submitted.
81. Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999; 4: 106-12.
82. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol 2000; 31: 222-5.
83. Olafsson D, Berstad A, Bang CJ, et al. Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole. Aliment Pharmacol Ther 1999; 13: 651-9.
84. Lu H, Zhang DZ, Hu PJ, et al. One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized double-blind study. Aliment Pharmacol Ther 2001; 15: 1975-9.
85. Mégraud F, Marshall BJ, How to treat Helicobacter pylori. Firstline, second-line, and future therapies. Gastroenterol Clin N Am 2000; 29: 759-73.
86. Peitz U, Glasbrenner B, Ellenrieder V, et al. Re-treatment of H. pylori infection with high dose omeprazole-amoxicillin after failure with metronidazole-clarithromycin combination. Gut 1999; 45: A111(Abstract).
87. Jaup BH, Dual 'rescue' therapy for eradication of H. pylori in previous triple therapy failure. Gut 1999; 45: A118(Abstract).
88. Toracchio S, Cellini L, Di Campli E, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1639-43.
89. Romano M, Iovene MR, Montella F, Vitale LM, De Simone T, Del Vecchio Blanco C. Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection. Am J Gastroenterol 2000; 95: 3317-8.
90. Oleastro M, Ménard A, Santos A, et al. Rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori by real-time PCR. J Clin Microbiol 2003; 41: 397-402.